Your session is about to expire
← Back to Search
SGLT2 Inhibitor
Dapagliflozin 10 MG [Farxiga] for Kidney Failure
Phase 4
Waitlist Available
Led By Hiddo JL Heerspink
Research Sponsored by George Clinical Pty Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
Study Summary
This study is evaluating whether a drug called dapagliflozin might help lower blood sugar levels in people with type 2 diabetes.
Eligible Conditions
- Kidney Failure
- Type 2 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in 24-hr sodium excretion
Side effects data
From 2018 Phase 4 trial • 30 Patients • NCT0300647120%
Cervicovaginal infection
13%
Urinary tract infections
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dapagliflozin
Placebo
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
FDA approved
Find a Location
Who is running the clinical trial?
George Clinical Pty LtdLead Sponsor
13 Previous Clinical Trials
21,275 Total Patients Enrolled
Ground Zero PharmaceuticalsIndustry Sponsor
2 Previous Clinical Trials
57 Total Patients Enrolled
University Medical Center GroningenOTHER
721 Previous Clinical Trials
982,677 Total Patients Enrolled
2 Trials studying Kidney Failure
1,541 Patients Enrolled for Kidney Failure
Share this study with friends
Copy Link
Messenger